Last Updated : April 4, 2022
Details
FilesGeneric Name:
trientine hydrochloride
Project Status:
Complete
Therapeutic Area:
Wilson's Disease
Manufacturer:
Waymade PLC
Brand Name:
Waymade-Trientine
Project Line:
Reimbursement Review
Project Number:
SR0696-000
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Waymade-Trientine (trientine hydrochloride) is indicated for the treatment of patients with Wilson's Disease who are intolerant of penicillamine.
Submission Type:
Initial
Fee Schedule:
Schedule A
Tumour Type:
N/A
Indications:
Waymade-Trientine (trientine hydrochloride) is indicated for the treatment of patients with Wilson's Disease who are intolerant of penicillamine.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2 | |
|---|---|
| Call for patient/clinician input open | June 02, 2021 |
| Call for patient/clinician input closed | July 23, 2021 |
| Clarification: - Patient input submission received from Canadian Liver Foundation | |
| Submission received | July 21, 2021 |
| Submission accepted | August 05, 2021 |
| Review initiated | August 06, 2021 |
| Draft CADTH review report(s) provided to sponsor for comment | November 04, 2021 |
| Deadline for sponsors comments | November 15, 2021 |
| CADTH review report(s) and responses to comments provided to sponsor | December 03, 2021 |
| Expert committee meeting (initial) | December 15, 2021 |
| Draft recommendation issued to sponsor | January 04, 2022 |
| Draft recommendation posted for stakeholder feedback | January 13, 2022 |
| End of feedback period | January 27, 2022 |
| Final recommendation issued to sponsor and drug plans | February 08, 2022 |
| Final recommendation posted | February 25, 2022 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | February 23, 2022 |
| CADTH review report(s) posted | April 04, 2022 |
Files
Last Updated : April 4, 2022